Table 1.
Demographic and clinical data of the cohort
| n (%) | Mean (95% CI) | |
|---|---|---|
| Female sex | 13/18 (72.2%) | |
| Age, years | 35.4 (29.9–40.9) | |
| Steroid dose, mg | 6,555.6 (4,797.6–8,313.5) | |
| Affected eye | ||
| Left | 13/18 (72.2%) | |
| Right | 4/18 (22.2%) | |
| Bilateral | 1/18 (5.6%) | |
| 1st event and MS diagnosis | 13/18 (72.2%) | |
| Immunotherapy | ||
| No | 15/18 (83.3%) | |
| Glatiramer acetate | 1/18 (5.6%) | |
| Interferon beta formulations | 2/18 (11.1%) | |
| Time intervals | ||
| Symptom onset to 1st steroid, days | 8.4 (4.2–12.5) | |
| Symptom onset to PLEX, days | 20.3 (14.8–25.9) | |
| Number of PLEX sessions (available for n = 17) | 6.5 (6.0–7.0) | |
| Setting of PLEX (fully ambulatory setting) | 10/18 (55.6%) | |
| PLEX aditus (fully via peripheral veins) | 13/18 (72.2%) | |
| Adverse events | ||
| Any | 13/18 (72.2%) | |
| Dizziness | 2/18 (11.1%) | |
| Hypocalcemic symptoms | 1/18 (5.6%) | |
| Hypotonia | 2/18 (11.1%) | |
| Low fibrinogen | 11/18 (61.1%) | |
| Muscular complaints | 1/18 (5.6%) | |
| Nausea | 2/18 (11.1%) | |
CI, confidence interval; MS, multiple sclerosis; PLEX, plasma exchange.